logo
Gender dysphoria should be treated with therapy instead of transition treatments, massive Donald Trump-ordered health report urges

Gender dysphoria should be treated with therapy instead of transition treatments, massive Donald Trump-ordered health report urges

Sky News AU02-05-2025

A sweeping review of transgender treatments on minors found 'deep uncertainty about the purported benefits' of many of those interventions — and urged doctors to put more of an emphasis on behavioral therapy when addressing gender dysphoria.
Researchers also concluded that many of the protocols for treating children with gender dysphoria became widely used before outcome studies determined whether or not they were safe practices, a massive 409-page Health and Human Services study revealed.
'The umbrella review found that the overall quality of evidence concerning the effects of any intervention on psychological outcomes, quality of life, regret, or long-term health, is very low,' HHS' Gender Dysphoria Report determined in its assessment of common studies on transgender treatments.
'This indicates that the beneficial effects reported in the literature are likely to differ substantially from the true effects of the interventions.'
President Trump signed an executive order in January ordering HHS to conduct a review of best practices for treating gender dysphoria within 90 days, which was released Thursday.
Transgender interventions in children that were scrutinized in the blockbuster HHS report include the use of puberty blockers, hormone therapy and surgeries.
While the report stressed it is not a 'clinical practice guideline,' the paper examined 17 systematic reviews of transgender treatments in minors and concluded that there was limited evidence to suggest those interventions had any 'meaningful improvement in mental health.'
In some instances, this was because studies did not properly measure track patient outcomes or studied individuals whose mental health was already at a 'high-functioning at baseline.'
'Multiple SRs [systematic reviews] have concluded that the evidence supporting the benefits of pediatric transition interventions—from PBs [puberty blockers] to CSH [cross-sex hormone therapy] and surgery—is of 'very low certainty,'' the HHS report said.
'All medical interventions carry the potential for harm.'
A lot of the research into transgenderism in question was conducted overseas. One of the most famous ones was the Dutch Protocol, which was originally published in 2006 and outlined 'highly medicalized' methods to treat young people with gender dysphoria, including puberty blockers.
For years, the Dutch Protocol was generally regarded as the gold standard guideline for treating young people struggling with gender dysphoria. The guidance has since been weakened over time, with some of its eligibility restrictions pared down.
Following the 2006 publication of the Dutch Protocol, there had been a sharp rise in transgender treatments in minors.
An estimated 3.3% of US adolescents consider themselves transgender, per the HHS report. Meanwhile, about 0.1% of 17-year-olds received hormonal treatment between 2018 and 2022.
But HHS researchers found that the Dutch Protocol was based on 'methodological flaws' that were 'largely overlooked' by the broader medical community since its publication.
'One of the study's limitations was its retrospective selection of 70 subjects from a larger 'intent-to-treat' group of 111 using non-randomized methods,' the HHS report said.
'This selection process inadvertently biased the sample toward cases with the most favorable prognoses, thereby limiting the generalizability of the study's findings.'
The HHS study cautioned that there is an 'extreme toxicity and polarization surrounding this field of medicine.'
Researchers in the HHS report frequently pointed to the United Kingdom's Cass Review, a sweeping four-year study by the National Health Service that similarly poked metholodical holes in more conventional research into transgenderism.
They also acknowledged that there's a 'growing international concern about pediatric medical transition' and that foreign countries are increasingly restricting transgender treatments on minors.
'There is currently no international consensus about best practices for the care of children and adolescents with gender dysphoria,' the HHS report stressed.
Still, the medical ethicists, doctors and methodologies that put the HHS review together highlighted the potential benefits of psychotherapeutic approaches to tackling gender dysphoria in minors.
HHS researchers admitted that 'direct evidence for psychotherapy' in children with gender dysphoria is limited, but argued there is 'available evidence to support the role of psychotherapy intreating children and adolescents with other mental health problems, like depression.
The HHS study has been met with mixed reactions from the medical community.
Susan Kressly, the president of the American Academy of Pediatrics, slammed the report, arguing that it relied too heavily upon a 'narrow set of data' and 'select perspectives.
'This report misrepresents the current medical consensus and fails to reflect the realities of pediatric care,' she said in a statement.
Dr. Stanley Goldfarb, chairman of Do No Harm, an organization that opposes so-called gender transition surgeries, hailed the HHS review for exposing 'a number of serious risks in the medical transition of young people.'
'The report cites a 'lack of robust evidence' for these medical procedures,' Goldfarb said in a statement. 'It is clearer now, more than ever, that we must end this misguided practice and replace it with evidence-based treatment for gender confused kids.'
Trump's directive for the HHS study was nestled in a broader January executive order to cut off government funding to support or promote operations for child sex changes.
National Institutes of Health (NIH) Director Dr. Jay Bhattacharya, whose agency helped conduct the HHS study, underscored the need to not let political agendas interfere with science.
'Our duty is to protect our nation's children—not expose them to unproven and irreversible medical interventions,' Bhattacharya said. 'We must follow the gold standard of science, not activist agendas.'
Now that it has been released, the HHS study, titled 'Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices,' is set to get peer-reviewed.
A modified version of the report is expected once the peer review process is complete.
Originally published as Gender dysphoria should be treated with therapy instead of transition treatments, massive Donald Trump-ordered health report urges

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr ousts entire US vaccine panel over alleged conflicts
RFK Jr ousts entire US vaccine panel over alleged conflicts

News.com.au

time3 days ago

  • News.com.au

RFK Jr ousts entire US vaccine panel over alleged conflicts

US Health Secretary Robert F. Kennedy Jr. on Monday announced he was dismissing all current members of a key federal vaccine advisory panel, accusing them of conflicts of interest -- his latest salvo against the nation's immunization policies. The removal of all 17 experts of the Advisory Committee on Immunization Practices (ACIP) was revealed in a Wall Street Journal op-ed and an official press release. Kennedy, who has spent two decades promoting vaccine misinformation, cast the move as essential to restoring public trust, claiming the committee had been compromised by financial ties to pharmaceutical companies. "Today we are prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda," he said in a statement from the Department of Health and Human Services. "The public must know that unbiased science -- evaluated through a transparent process and insulated from conflicts of interest — guides the recommendations of our health agencies." In his op-ed, Kennedy claimed the panel was "plagued with persistent conflicts of interest" and had become "little more than a rubber stamp for any vaccine." He added that new members were being considered to replace those ousted -- all of whom were appointed under former president Joe Biden. ACIP members are chosen for their recognized expertise and are required to disclose potential conflicts of interest. "RFK Jr. and the Trump administration are taking a wrecking ball to the programs that keep Americans safe and healthy," Senate Democratic Leader Chuck Schumer said in response. "Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion," Republican Senator Bill Cassidy, a medical doctor who expressed concern about Kennedy's track record during his Senate nomination but ultimately voted in his favor, wrote on X. "I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case." - 'Silencing expertise' - The decision drew sharp criticism from Paul Offit, a pediatrician and leading expert on virology and immunology who served on the panel from 1998 to 2003. "He believes that anybody who speaks well of vaccines, or recommends vaccines, must be deeply in the pocket of industry," Offit told AFP. "He's fixing a problem that doesn't exist." "We are witnessing an escalating effort by the Administration to silence independent medical expertise and stoke distrust in lifesaving vaccines," added Susan Kressly, president of the American Academy of Pediatrics, in a statement. Once a celebrated environmental lawyer, Kennedy pivoted from the mid-2000s to public health -- chairing a nonprofit that discouraged routine childhood immunizations and amplified false claims, including the long-debunked theory that the Measles, Mumps and Rubella (MMR) vaccine causes autism. Since taking office, he has curtailed access to Covid-19 shots and continued to raise fears around the MMR vaccine -- even as the United States faces its worst measles outbreak in years, with three reported deaths and more than 1,100 confirmed cases. Experts warn the true case count is likely far higher. "How can this country have confidence that the people RFK Jr. wants on the Advisory Committee for Immunization Practices are people we can trust?" Offit asked. He recalled that during US President Donald Trump's first term, several states formed independent vaccine advisory panels after the administration pressured federal health agencies to prematurely approve Covid-19 vaccines ahead of the 2020 election. That kind of fragmentation, Offit warned, could happen again. ACIP is scheduled to hold its next meeting at the headquarters of the Centers for Disease Control and Prevention in Atlanta from June 25 to June 27. ia/jgc

ASX health May winners: Sector rises 1.59pc but market volatility remains
ASX health May winners: Sector rises 1.59pc but market volatility remains

News.com.au

time03-06-2025

  • News.com.au

ASX health May winners: Sector rises 1.59pc but market volatility remains

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump's trade and health policies continue to impact sector Lumos up 7.4% in May after several positive announcements including largest single purchase order for point-of-care respiratory test The S&P/ASX 200 Health Care Index rose 1.59% in May, easing from a 2.16% gain in April but still finishing in the green. However, the sector is still not faring well and is the worst-performing year-to-date, down 5.65%. The sector rose in line with broader markets in May with the S&P/ASX 200 gaining 4.20% as fears around escalating US tariffs and a potential US-China trade war eased, bringing relief to global markets. Morgans healthcare analyst Iain Wilkie told Stockhead that 2025 had been very volatile for the sector. "Each month seems to be either up or down and the sector hasn't gained any real momentum at this stage," he said. Wilkie said US President Donald Trump and his trade and health policies were still impacting the sector. "It's just uncertainty which is driving everything at the moment," he said. In May Trump signed an executive order lowering prices of US prescription medicines to bring them in line with other countries, a policy referred to as the 'most favored nation' (MFN). The MFN policy aims to link US drug prices to much lower prices overseas – what Trump referred to as 'equalizing' prices. Trump said the order aimed to cut US pharmaceutical prices from between 59% to 90% and sets price targets for drugmakers to meet within 30 days and warns that further action will be taken if they fail to make 'significant progress' toward those goals. In a release The White House said the US had less than 5% of the world's population and yet funds around three quarters of global pharmaceutical profits. "There's no clear path on what happens next and consequences pharmaceutical companies may face," Wilkie said. "But its just created further uncertainty in the healthcare and pharmaceutical sectors in an already uncertain time." How ASX biotechs performed in May CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP DVL Dorsavi Ltd $ 0.02 36.4% 10.97 IVX Invion Ltd $ 0.11 28.0% 8.47 CC5 Clever Culture $ 0.02 26.7% 33.55 VFX Visionflex Group Ltd $ 0.003 25.0% 8.42 NYR Nyrada Inc $ 0.18 24.1% 37.97 IIQ Inoviq Ltd $ 0.55 23.9% 63.07 OSX Osteopore Limited $ 0.02 21.4% 2.95 PEB Pacific Edge $ 0.09 18.7% 60.89 ICR Intelicare Holdings $ 0.01 14.3% 3.89 MVP Medical Developments $ 0.67 11.7% 75.48 PCK Painchek Ltd $ 0.06 11.5% 106.83 IRX Inhalerx Limited $ 0.03 11.1% 6.40 ALA Arovella Therapeutic $ 0.08 11.0% 88.79 IPD Impedimed Limited $ 0.03 10.0% 66.91 LGP Little Green Pharma $ 0.11 10.0% 34.96 ATH Alterity Therapeutics $ 0.01 10.0% 100.40 DOC Doctor Care Anywhere $ 0.11 10.0% 38.50 AGH Althea Group $ 0.03 8.7% 20.56 ALC Alcidion Group Ltd $ 0.09 8.6% 114.15 HMD Heramed Limited $ 0.01 8.3% 11.38 MDR Medadvisor Limited $ 0.09 8.1% 57.48 RAD Radiopharm $ 0.03 8.0% 65.35 LDX Lumos Diagnostics $ 0.03 7.4% 21.71 AVR Anteris Technologies $ 6.29 6.6% 99.41 AFP AFT Pharmaceuticals $ 2.60 6.1% 272.65 ARX Aroa Biosurgery $ 0.49 5.4% 165.55 UCM Uscom Limited $ 0.02 5.3% 4.76 RHC Ramsay Health Care $ 37.90 5.1% 7,049.83 CVB Curvebeam Ai Limited $ 0.09 4.9% 26.97 REG Regis Healthcare Ltd $ 8.13 4.9% 1,242.92 TRI Trivarx Ltd $ 0.01 4.8% 6.79 ACR Acrux Limited $ 0.02 4.3% 9.79 VLS Vita Life Sciences $ 1.89 4.1% 104.29 PGC Paragon Care Limited $ 0.40 3.9% 662.12 NSB Neuroscientific $ 0.06 3.8% 7.95 CMP Compumedics Limited $ 0.28 3.7% 53.82 SPL Starpharma Holdings $ 0.09 3.4% 38.48 NOX Noxopharm Limited $ 0.07 2.9% 21.04 GLH Global Health Ltd $ 0.08 2.6% 4.63 CMB Cambium Bio Limited $ 0.21 2.5% 3.75 PIQ Proteomics Int Lab $ 0.42 2.4% 59.56 SDI SDI Limited $ 0.85 2.4% 99.25 CSX Cleanspace Holdings $ 0.45 2.3% 34.81 ATX Amplia Therapeutics $ 0.05 2.0% 19.40 MVF Monash IVF Group Ltd $ 0.78 2.0% 301.97 IDX Integral Diagnostics $ 2.43 1.9% 870.95 EZZ EZZ Life Science $ 1.54 1.7% 72.65 IMC Immuron Limited $ 0.07 1.5% 15.67 FRE Firebrickpharma $ 0.07 1.5% 15.05 SHL Sonic Healthcare $ 26.62 1.4% 12,821.98 FPH Fisher & Paykel Healthcare $ 34.59 1.4% 6,585.46 IMR Imricor Med Systems $ 1.67 1.2% 541.55 OCC Orthocell Limited $ 1.27 1.2% 307.31 PME Pro Medicus Limited $ 280.98 0.9% 15,316.67 PAR Paradigm Biopharmaceuticals $ 0.31 0.8% 120.72 CTE Cryosite Limited $ 0.75 0.7% 36.61 CHM Chimeric Therapeutic $ 0.00 0.0% 8.06 IXC Invex Therapeutics $ 0.09 0.0% 6.99 COV Cleo Diagnostics $ 0.35 0.0% 27.74 IDT IDT Australia Ltd $ 0.10 0.0% 45.12 EYE Nova EYE Medical Ltd $ 0.13 0.0% 35.52 OCA Oceania Healthc Ltd $ 0.59 0.0% 427.30 EPN Epsilon Healthcare $ 0.02 0.0% 8.29 TD1 Tali Digital Limited $ 0.00 0.0% 3.30 OIL Optiscan Imaging $ 0.13 0.0% 112.77 PER Percheron $ 0.01 0.0% 10.87 OSL Oncosil Medical $ 1.20 0.0% 13.82 BIT Biotron Limited $ 0.00 0.0% 3.32 EOF Ecofibre Limited $ 0.02 0.0% 7.58 TRP Tissue Repair $ 0.19 0.0% 11.19 IBX Imagion Biosys Ltd $ 0.01 0.0% 2.42 SOM SomnoMed Limited $ 0.59 0.0% 129.66 ANR Anatara Ls Ltd $ 0.01 0.0% 1.07 HIQ Hitiq Limited $ 0.02 0.0% 7.57 ADR Adherium Ltd $ 0.01 0.0% 5.31 PSQ Pacific Smiles Grp $ 1.81 -0.3% 291.73 COH Cochlear Limited $ 271.60 -0.4% 17,779.29 CSL CSL Limited $ 247.16 -0.7% 119,986.49 TLX Telix Pharmaceutical $ 25.98 -0.8% 7,546.94 HLS Healius $ 0.88 -0.8% 635.37 ANN Ansell Limited $ 31.19 -0.9% 4,566.62 SNZ Summerset Grp Hldgs $ 10.21 -0.9% 2,461.11 MYX Mayne Pharma Ltd $ 4.80 -1.0% 376.51 RGT Argent Biopharma Ltd $ 0.09 -1.1% 6.86 PNV Polynovo Limited $ 1.27 -1.2% 870.46 PYC PYC Therapeutics $ 1.20 -1.2% 699.91 BDX Bcal Diagnostics $ 0.08 -1.3% 27.45 NEU Neuren Pharmaceuticals $ 13.85 -1.4% 1,765.00 RMD ResMed Inc. $ 37.58 -1.5% 22,360.10 IME Imexhs Limited $ 0.33 -1.5% 17.70 LTP LTR Pharma $ 0.32 -1.5% 34.71 AHC Austco Healthcare $ 0.31 -1.6% 112.86 RHY Rhythm Biosciences $ 0.06 -1.6% 17.87 ONE Oneview Healthcare $ 0.27 -1.9% 202.31 VHL Vitasora Health Ltd $ 0.04 -2.4% 66.24 MSB Mesoblast Limited $ 1.60 -2.4% 1,560.40 CYC Cyclopharm Limited $ 1.18 -2.5% 131.70 AHX Apiam Animal Health $ 0.39 -2.5% 71.74 EBO Ebos Group Ltd $ 34.69 -2.5% 1,365.85 IMM Immutep Ltd $ 0.28 -2.6% 407.57 VIT Vitura Health Ltd $ 0.07 -2.9% 45.03 CUV Clinuvel Pharmaceuticals $ 10.24 -3.0% 457.13 AVH Avita Medical $ 1.89 -3.1% 123.08 NAN Nanosonics Limited $ 4.39 -3.1% 1,282.02 NUZ Neurizon Therapeutic $ 0.15 -3.3% 68.92 MAP Microba Life Sciences $ 0.15 -3.3% 64.94 BMT Beamtree Holdings $ 0.28 -3.4% 81.15 SIG Sigma Health Ltd $ 3.06 -3.5% 17,428.00 MX1 Micro-X Limited $ 0.06 -3.5% 36.70 CGS Cogstate Ltd $ 1.30 -3.5% 219.41 NC6 Nanollose Limited $ 0.05 -3.8% 15.24 RCE Recce Pharmaceutical $ 0.34 -4.2% 90.39 AYA Artrya $ 0.73 -4.6% 82.43 ACW Actinogen Medical $ 0.02 -4.8% 63.54 DXB Dimerix Ltd $ 0.58 -4.9% 326.72 ACL Au Clinical Labs $ 2.78 -5.1% 395.94 EBR EBR Systems $ 1.09 -5.2% 465.57 NXS Next Science Limited $ 0.07 -5.6% 19.57 EMV Emvision Medical $ 1.68 -5.6% 140.67 AT1 Atomo Diagnostics $ 0.02 -5.9% 10.98 PTX Prescient Ltd $ 0.05 -6.0% 37.85 AGN Argenica $ 0.77 -6.1% 98.63 M7T Mach7 Tech Ltd $ 0.35 -6.7% 84.43 BOT Botanix Pharma Ltd $ 0.35 -6.8% 620.71 ZLD Zelira Therapeutics $ 0.46 -7.1% 5.71 SNT Syntara Limited $ 0.07 -7.1% 105.57 CAN Cann Group Ltd $ 0.01 -7.1% 8.09 TYP Tryptamine Ltd $ 0.03 -8.6% 44.45 NTI Neurotech International $ 0.02 -8.7% 22.04 SHG Singular Health $ 0.30 -9.1% 83.31 ECS ECS Botanics Holding $ 0.01 -9.1% 14.26 GSS Genetic Signatures $ 0.49 -9.3% 110.16 CBL Control Bionics $ 0.03 -9.7% 8.84 ILA Island Pharma $ 0.21 -10.6% 49.05 UBI Universal Biosensors $ 0.04 -10.6% 12.52 EMD Emyria Limited $ 0.03 -10.7% 13.75 TRU Truscreen $ 0.02 -11.1% 13.32 RHT Resonance Health $ 0.04 -11.6% 20.22 RAC Race Oncology Ltd $ 1.21 -12.0% 210.22 4DX 4DMedical Limited $ 0.31 -12.9% 146.64 CYP Cynata Therapeutics $ 0.17 -13.2% 37.28 CU6 Clarity Pharma $ 1.91 -13.8% 535.84 CDX Cardiex Limited $ 0.04 -16.1% 17.87 1AI Algorae Pharma $ 0.01 -16.7% 8.44 TRJ Trajan Group Holding $ 0.77 -16.8% 116.57 IMU Imugene Limited $ 0.01 -17.6% 112.01 MEM Memphasys Ltd $ 0.00 -18.2% 7.93 AVE Avecho Biotech Ltd $ 0.00 -20.0% 12.69 BP8 Bph Global Ltd $ 0.00 -20.0% 2.10 VBS Vectus Biosystems $ 0.05 -21.7% 2.50 CTQ Careteq Limited $ 0.01 -23.1% 2.37 1AD Adalta Limited $ 0.00 -33.3% 1.93 Inoviq (ASX:IIQ) rose ~24% in May and got hit with a speeding ticket by the ASX. The oncology play had no particular news out in May and attributed the increase to publication online of an abstract accepted by the American Society of Clinical Oncology (ASCO) for a poster presentation about results of its EXO-OC test for ovarian cancer. Inoviq said the result had already been released in December and referred to in subsequent business updates. "Some shareholders may have missed or misunderstood the significance of our 3 December 2024 ASX release and subsequent related updates noted above and may believe the Abstract contains new or better information, which is materially price sensitive, that is not the case in the company's view. The company said new information to be delivered in the poster presentation at the ASCO annual meeting on June 1 was "considered price sensitive". On June 2 Inoviq announced that new data presented at the ASCO meeting showed its EXO-OC test achieved 77% sensitivity at 99.6% specificity for detecting ovarian cancer at all stages. Clever Culture Systems (ASX:CC5) continued to build momentum in May and was up 26.7% for the month after announcing a positive quarterly update in April, including its second quarter of positive cashflow. Clever Culture is targeting profitability in FY25 and building a substantial sales pipeline to underpin growth in FY26 for its APAS Independence instruments, which remain the only US FDA-cleared AI technology for automated culture plate reading. Lumos Diagnostics (ASX:LDX) rose 7.4% in May after several positive announcements including the largest single purchase order to date for its FebriDx test, a rapid point-of-care (POC) diagnostic designed to differentiate between bacterial and non-bacterial acute respiratory infections. Developer and distributor of cost-saving solutions for hospitals, surgery centres, clinics and healthcare facilities across the US iMedical purchased US$126,000 worth of FebriDx tests. In May Lumos also expanded Medicare reimbursement coverage in the US for FebriDx. By the end of May Lumos had secured reimbursement from six out of seven US Medicare Administrative Contractors (MACs) representing over 85% of US Medicare payment coverage. And Australia's biggest private hospital operator Ramsay Health Care (ASX:RHC) rose 5.1% in May after providing a positive update on its 52.8% stake in European hospitals business Santé, with unaudited group revenue for the nine months period ending March 31, up by 5.1%.

Brisbane news live: Queensland ‘needs an extra 350 mental health beds'
Brisbane news live: Queensland ‘needs an extra 350 mental health beds'

The Age

time28-05-2025

  • The Age

Brisbane news live: Queensland ‘needs an extra 350 mental health beds'

Latest posts Latest posts 7.13am Queensland hospital system needs an extra 350 mental health beds: psychiatrists By The imminent closure of Toowong Private Hospital will leave Queensland with a shortfall of 350 mental health beds, according to the Royal Australian and New Zealand College of Psychiatrists. Loading Administrators called in to examine the family-owned hospital have decided to shut it down, and are now working with psychiatrists to ensure continuity of care for existing and prospective patients. Professor Brett Emmerson, chair of the college's Queensland branch, said there were not enough psychiatrists to run private hospitals, partly because the financial incentives were low and support was lacking. He said the federal government needed to increase Medicare rebates and ensure private health funds paid more, while also increasing training places for psychiatry. The state government also needed to invest in new beds, particularly when the existing beds are old and in such high demand. 'A viable private sector is essential in Queensland because we've got an already overstretched mental health system,' Emmerson said. He said the loss of 50 beds at Toowong would further reduce inpatient treatment options for private patients and increase pressure on the public system. 7.05am Cool and cloudy to close the week Another cool day is on the cards for Brisbane today, with the Bureau of Meteorology predicting a top of 23 degrees on a cloudy Thursday. And the forecast is for an even cooler Friday. Here's the seven-day outlook: 7.02am While you were sleeping Here's what's making news further afield this morning: Liberal leader Sussan Ley has broken from the Dutton era with a reshuffle that rejects Trump-like cuts, goes softer on immigration, and proactively reaches out to women in the cities. A Christian pastor who founded a drug rehab centre that once treated former game show host Andrew O'Keefe has been charged with faking reports about patients' drug use. Police dug into Erin Patterson's bank records, shopping history and phone records as part of their investigation into a lunch that killed three of her guests, a court has heard. Real estate listings companies such as the Murdoch-controlled REA Group are making off like bandits with claims that advertising rates are rising by 10 per cent or more a year. And the ACCC has started sniffing around. 6.35am The top stories this morning Good morning, and welcome to Brisbane Times' live news coverage for Thursday, May 29. Today we can expect a partly cloudy day and a top temperature of 23 degrees. In this morning's local headlines: There was an eerie sense of deja vu in the way the Maroons were blown off the park at Suncorp Stadium in the opening 40 minutes of the first State of Origin match last night, and it is a matter coach Billy Slater urgently needs to address. Here's how the players rated. The federal government is yet to recommit to its $3.44 billion contribution to Brisbane 2032 Olympic infrastructure after an inner-city arena was removed from the Games plan. And on his second visit to Brisbane, the international Paralympics chief says he has no intention of combining the Paralympics with the Olympics in 2032. More than 80 days after the Story Bridge's footpaths were closed, the saga has taken a dramatic turn, with police taking protesters to court over plans to close traffic lanes for a peak-hour march. When reporter Courtney Kruk recently found herself questioning a 4.8-star rating, she wondered whether we're all becoming too hooked on online reviews.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store